NASDAQ NMS - GLOBAL MARKET · FLNA
+7.25% · +$0.0700 · Vol 681.4K
Live · updated 11:54:41 ET
Filana Therapeutics Inc

Filana Therapeutics Inc

Pharmaceuticals
$1.03
Card
Relationship Map

Follow $FLNA

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $FLNA by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
FLNA
Filana Therapeutics Inc
Thu Oct 1 · last completed session · daily score · 17h old
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

82/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Thu Oct 1 · last completed session · daily score · 17h old
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is FLNA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading FLNA catalysts
About Filana Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2000
Employees
20
Country
US

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.9650
Day high
$1.04
Day low
$0.9501
Previous close
$0.9650
52W high
$2.09
-50.48% from high
52W low
$0.6842
25% of range
Market cap
$46.6M
EPS
$-0.2100
Beta
1.57
Shares out
48.3M
Volume
681.4K
0.18× rel vol
Avg volume
3.8M
VWAP
$1.01
Price history computed in-house
1W
+38.35%
1M
+20.69%
3M
-15.85%
SMA 50 $0.8843 · above
SMA 200 Not reported · Not reported
52W position 25%

FLNA overview

Veridion Score
82
Registered · 2026-10-01
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around FLNA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading FLNA Form 4 filings
Public disclosures

Congress activity in FLNA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for FLNA in the cached public ledger.

Federal contracts

FLNA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for FLNA in this window.
Lobbying spend

FLNA lobbying filings, year to date.

Registered lobbying filings matched to Filana Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for FLNA in this window.
Loading news for FLNA
Analyst ratings
Sovereign unlock shows live analyst consensus for FLNA.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.